We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Flying Brand | LSE:FBDU | London | Ordinary Share | JE00BD4H0R42 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.40 | 2.60 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 2.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/7/2023 | 07:00 | RNSNON | IQ-AI Limited Imaging Biometrics Installs IB Nimble(TM) For MCW |
| 27/6/2023 | 07:00 | RNSNON | IQ-AI Limited Studies Show GaM Inhibits Pediatric Tumor Growth |
Flying Brand (FBDU) Share Charts1 Year Flying Brand Chart |
|
1 Month Flying Brand Chart |
Intraday Flying Brand Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/10/2018 | 10:13 | Flying Brands | 646 |
| 03/10/2018 | 08:09 | A new start but will what comes next FLY? | 214 |
| 07/8/2008 | 18:03 | Flying Brands - imminent acqusition CHART EXCELLENT | 267 |
| 07/8/2008 | 17:38 | Flying Brands 2005 - Fly FBDU Fly! | 335 |
| 17/3/2004 | 23:22 | Should this be priced as a dot.com now? | 76 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 07/9/2018 19:41 by draft11 Opinion: No OpinionPrice: 2.25 Aycan systems Today 11:29 Rochester, New York, January 17, 2018. aycan, a recognized worldwide leader in medical imaging, in conjunction with business partner Imaging Biometrics, a company specializing in the development of software solutions for advanced visualization and analytics, announced today that Stanford University’s 3D and Quantitative Imaging Laboratory will utilize aycan workstation with Imaging Biometrics software to image brain tumors in patients and assess their response to treatment. Among the Imaging Biometrics (IB) software the Stanford Lab will run on aycan workstation is IB Rad Tech, which makes the generation of IB’s exclusive and sophisticated image maps, such as FTB (fractional tumor burden), easy and repeatable. Standardized FTB (sFTB) maps include exclusive image-intensity standardization technology, which enables quantitative and rapid longitudinal comparison on magnetic resonance (MR) imaging. aycan workstation is an FDA 510(k) cleared, vendor-neutral, highly functional advanced image-processing tool and DICOM PACS workstation for conventional, multi-slice and other image reading. IB’s full suite of FDA cleared software is available for aycan workstation, and includes IB Rad Tech, IB Neuro, IB DCE, IB Delta Suite, and IB Diffusion. |
Posted at 07/11/2017 10:25 by andrbea Today 10:07 jack_allis Research NoteSome good points made here; |
Posted at 06/11/2017 10:53 by andrbea LSe board more upbeat:Today 10:26 Wisha Yep the market is forward thinking, i believe this will start a re rate to price this in over the next few weeks, say to a conservative 10p then when we get confirmation of sales we will have the massive 100% rise in a day taking us to around 20p by end of Q1, imo |
Posted at 06/11/2017 10:32 by woodcutter Unless I'm missing something I thought this was pretty cleary Freddy. The volume and timing of when they can be converted isn't so important to me as at some point they'll all get converted and that's a significant dilution. There's only been a small portion converted at present and the values in my previous post for those outstanding seem pretty much confirmed by the RNS link here.woody |
Posted at 03/11/2017 09:11 by andrbea more on LSE fbdu boardeg RE: FBDU chats to Andrew ScottThu 17:30Good stuff, C/E anticipated for mid December and sales as early as Q1 2018. Not to mention the very interested partner in the states which i assume we will find out a lot more about once we get FDA approval in Q2 2018. |
Posted at 04/8/2017 12:50 by dudleym1975 Ramped share by the same twitter group |
Posted at 04/8/2017 09:33 by andrbea up 5%lse board says: Tue 01:26 EarlyInvestor All about the mrkt cap here not SP Its all about the tiny market cap here. Even at 50p its trading at similar valuations to peers. A long way to go on up from here Really excited about the weeks and months for FBDU Ceo has massive skin in the game as well Expect FBDU to be the biggest multi bagger of the year Watch this space folks |
Posted at 07/7/2017 20:28 by hedgehog 100 yasX4 Jul '17 - 00:41 - 189 of 191 1 0"Your points are duly noted. I have laid out just some of the significant concerns that exist ... " YasX, A major concern of mine, and one which seems to have been missed by the prospectus, is the heavy reliance on non-recurring revenues. This means that a continual stream of new customers will be needed just to maintain sales at the same level ... which may be difficult once the 'low-hanging fruit' is exhausted. That's one reason why medical equipment companies tend to be lowly-rated compared to biotechs. Furthermore, the relatively small amount of money raised leaves little room for error, but experience tells me that the vast majority of start-ups do not meet their projections - maybe one in a hundred or so does. The company is targeting a penetration rate of 3 - 4% of the kidney stone market in the UK for StoneChecker in the first 12 months from launch, a level which it seems to regard as low. However, capturing even a few % of a market is pretty high, and can be challenging to achieve. Trevor Brown has shown that's he's prepared to back FBDU at 1.1p and 1.5p, but at the moment investors are being asked to pay about two or three times those prices, which looks too high given the risks. Speculative stocks like this can often boom for a while on newsflow before crashing back, so there may be money to be made here as a trading punt, but at the current price of 3.25p there are more attractive risk-reward ratios elsewhere. P.S. There is also a potential overhand from Peterhouse: "E.1 Total net proceeds / expenses The Net Proceeds of the Placing are approximately £416,562. The total expenses incurred (or to be incurred) by the Company in connection with Admission, the Acquisition and the Placing are approximately £184,688, however Peterhouse will be taking their commission of £41,250 and fees of £10,000 (which have been included in the total expenses figure) through the issue of Ordinary Shares at Admission." |
Posted at 05/7/2017 15:12 by hedgehog 100 03/07/2017 07:00 UKREG Flying Brands Limited Conversion of Convertible Loan Notes into Equity"… Following this conversion, Flying Brands has GBP213,800 of Convertible Loan Notes outstanding and GBP100,000 of convertible loan notes issued pursuant to a loan note instrument dated 18 November 2015 outstanding. … On Admission, the Company will have 64,786,721 Ordinary Shares in issue. …" Monday's RNS highlights the large number of convertible loan notes outstanding: 213,800 convertible @ 1.1p, = 19,436,363 new shares if converted 100,000 convertible @ 1.5p, = 6,666,667 new shares if converted = 26,103,030 new shares if all converted + 64,786,721 shares currently in issue, would = 90,889,751 shares, i.e. a 40.3% increase At the current FBDU share price of 3.125p, that would equate to a market capitalisation of £2.84M. Conversion of these convertible loan notes doesn't bring in any more cash, as the money was subscribed in 2015, although it does reduce/remove the convertible loan debt. |
Posted at 03/7/2017 11:13 by yasx *If this has the ability to 'revolutionise' a billion dollar market in the near term, why did Feedback, who essentially developed it, let it go to Trevor Brown for 45k only months ago?*If it so clear to you that this will capture billions or tens of millions in sales very soon, why did the founder sell it to Feedback last year for one grand? *Why did Brown sell it to FBDU last month for 240k rather than keeping this gargantuan business soon to be yielding billions for himself? Philanthropy? "the aggregate purchase price for the Target, on the basis that 8,000,000 Consideration Shares would still be issued to the Sellers, is now £240,000 as the Company’s share price at suspension was £0.03" *As for all these sales,it is not even ready to be sold, nor is it even certain that it will clear hurdles to be able to be sold. From the prospectus last month: " In the event that the results from the fourth study are unsatisfactory the StoneChecker product may require further trials in order to prove whether or not it is capable of commercial sales" FBDU's words, not mine. *This is what the Co. expects in terms of next years sales: "it will be possible to sell 30 units of the one-off server version of the software in the UK during the first twelve months of launching the StoneChecker product at a target price of £15,000 per licence" ie £450k. That is sales, not profit. So, strip out all the cash and investment to get to that stage, hardly a monumental offering is it. Obviously, the 450k raised is all but accounted for (the prospectus details in itemised form how the funds will be used for purposes of ongoing trials and obtaining regulatory approvals. Where will they get additional funds from to develop and market this next year? Don't ask me, ask the Co, it clearly states: "Once the Net Proceeds have been exhausted, the Company will be dependent on the income generated by the Target and its business to meet the Company’s expenses and operating cash requirements" Think those 450k in anticipated sales not likely to go very far next year... |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
